Diabetes Board decisions

The Board denied service connection for diabetes mellitus type II, hypertension, peripheral vascular disease, and chronic kidney disease as they were not related to the Veteran's active service or herbicide exposure.

The Board denied service connection for gout and erectile dysfunction, remanded claims for service connection for Hepatitis C, hypertension, liver cancer, diabetes mellitus, cirrhosis of the liver, lumbosacral strain with degenerative arthritis, headaches, memory loss, and the Veteran's cause of death, and referred claims for service connection for headaches, memory loss, and the Veteran's cause of death to the RO.

The Board denied service connection for diabetes mellitus on a basis other than the PACT Act, as there was no evidence of direct exposure to herbicides and the medical evidence did not support a direct causation theory.

The Board denied increased ratings for diabetes mellitus type II and right upper and left upper extremity peripheral neuropathies, but granted initial 40 percent ratings for right and left lower extremity diabetic neuropathies.

The Board dismissed the proposed severance of service connection for rhinitis and denied service connection for hypertension. The claims for service connection for diabetes mellitus type II and sinusitis were remanded.

The Board remands the claim for service connection for type II diabetes mellitus to ensure compliance with the PACT Act and to verify herbicide exposure during the Veteran's service in Korea.

The Board granted service connection for right shoulder arthritis, left shoulder arthritis, left wrist arthritis, left foot arthritis, and heart disability, to include coronary artery disease (CAD), as the evidence was approximately evenly balanced in favor of the Veteran. The claims for diabetes mellitus and kidney disability were remanded for further development.

The Board denied several claims for service connection and higher ratings, granted service connection for a right knee disability and a right wrist disability as secondary to the service-connected right little finger, fifth metacarpal, degenerative arthritis, and remanded other claims.

The Board granted service connection for coronary artery disease, diabetes mellitus, type II, and hypertension. The claims for tinnitus, bilateral hearing loss, and other conditions were denied or remanded.

The Board granted service connection for diabetes mellitus, type II and an initial rating of 30 percent for arteriosclerotic heart disease (CAD) with presence of coronary angioplasty implant and graft. Other claims were denied.

The Board granted service connection for type II diabetes mellitus, Non-Hodgkins Lymphoma, and hypertension as due to Agent Orange exposure.

The Board granted an effective date of March 31, 2014 for the award of service connection for type II diabetes mellitus and peripheral neuropathy, but denied an earlier effective date for tinnitus.

The Board denied service connection for all claimed conditions as there was no evidence of a current disability, in-service incurrence or aggravation, and no nexus between the current disabilities and military service.

The Board remands the claims for service connection for diabetes mellitus type II and bladder cancer due to insufficient evidence regarding potential toxic exposure risk activities, including burn pits.

The Board denied the claims for increased disability evaluations and effective dates, as well as dismissed the claims related to lung cancer and SMC on housebound status.

The Board denied the claim for service connection for the cause of the Veteran's death, as the evidence did not support a finding that any of the listed conditions were etiologically related to an in-service injury or disease.

The Board remands the claims for service connection for an acquired psychiatric disorder, diabetes mellitus, type II, hypertension, arthritis (other than of the back or neck), and a neck disability to obtain additional medical opinions addressing secondary service connection theories.

The appeal of the deferral decision on service connection for diabetic peripheral neuropathy was dismissed, and a rating of 20 percent for diabetes mellitus was granted.

The Board granted an effective date of September 26, 2022, for the award of service connection for diabetes mellitus, type II, and hypertension.

The Board granted service connection for diabetes mellitus type 2, Parkinson's disease, hypertension (under the PACT Act), prostate cancer, and erectile dysfunction. The claims for anemia, insomnia, and Alzheimer's disease were remanded.